Campbell & CO Investment Adviser LLC Has $235,000 Stock Holdings in NeoGenomics, Inc. $NEO

Campbell & CO Investment Adviser LLC lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,487 shares of the medical research company’s stock after selling 46,288 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in NeoGenomics were worth $235,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Moody National Bank Trust Division grew its stake in NeoGenomics by 1.4% in the third quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock valued at $698,000 after acquiring an additional 1,227 shares during the period. Moors & Cabot Inc. boosted its holdings in shares of NeoGenomics by 20.0% in the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock valued at $88,000 after buying an additional 2,000 shares during the period. State of Tennessee Department of Treasury increased its position in shares of NeoGenomics by 3.6% during the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock worth $425,000 after acquiring an additional 2,039 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of NeoGenomics by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 65,004 shares of the medical research company’s stock worth $475,000 after acquiring an additional 2,238 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in NeoGenomics by 7.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,041 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 2,323 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analysts Set New Price Targets

NEO has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of NeoGenomics in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Finally, Leerink Partners set a $14.00 target price on NeoGenomics in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, NeoGenomics has a consensus rating of “Hold” and a consensus price target of $12.00.

NeoGenomics Stock Performance

NEO opened at $12.81 on Friday. NeoGenomics, Inc. has a 12-month low of $4.72 and a 12-month high of $15.32. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -14.56 and a beta of 1.58. The business has a 50 day moving average of $12.09 and a 200-day moving average of $9.44. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The business had revenue of $187.80 million for the quarter, compared to analyst estimates of $183.85 million. During the same period in the previous year, the firm earned $0.05 EPS. The firm’s revenue was up 12.0% compared to the same quarter last year. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Insider Buying and Selling at NeoGenomics

In related news, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares in the company, valued at approximately $372,996. This represents a 40.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Warren Stone sold 22,128 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.40% of the stock is owned by insiders.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.